Exact Mass: 660.3159

Exact Mass Matches: 660.3159

Found 227 metabolites which its exact mass value is equals to given mass value 660.3159, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Coproporphyrinogen III

3-[9,14,20-tris(2-carboxyethyl)-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20),3,5,8,10,13,15,18-octaen-4-yl]propanoic acid

C36H44N4O8 (660.3159)


Coproporphyrinogen III is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrinogen III is a tetrapyrrole dead-end product resulting from the spontaneous oxidation of the methylene bridges of coproporphyrinogen arising from heme synthesis. It is secreted in feces and urine. Coproporphyrinogen III is biosynthesized from the tetrapyrrole hydroxymethylbilane, which is converted by the action of uroporphyrinogen III synthase to uroporphyrinogen III. Uroporphyrinogen III is subsequently converted into coproporphyrinogen III through a series of four decarboxylations. Increased levels of coproporphyrinogens can indicate congenital erythropoietic porphyria or sideroblastic anemia, which are inherited disorders. Porphyria is a pathological state characterized by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: (1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, (2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, and (3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors include disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss and diminished utilization of coproporphyrinogen in the hepatocytes. This may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine. Decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion. Therefore, the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function, intrahepatic cholestasis, and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms (PMID: 3327428). Under certain conditions, coproporphyrinogen III can act as a phototoxin, a neurotoxin, and a metabotoxin. A phototoxin leads to cell damage upon exposure to light. A neurotoxin causes damage to nerve cells and nerve tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of porphyrins are associated with porphyrias such as porphyria variegate, acute intermittent porphyria, hereditary coproporphyria (HCP), congenital erythropoietic porphyria, and sideroblastic anemia. In particular, coproporphyrinogen III is accumulated and excreted excessively in the feces in acute intermittent porphyria, protoporphyria, and variegate porphyria. There are several types of porphyrias (most are inherited). Hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain, and an acute polyneuropathy), while the erythropoietic forms present with skin problems (usually a light-sensitive blistering rash and increased hair growth). The neurotoxicity of porphyrins may be due to their selective interactions with tubulin, which disrupt microtubule formation and cause neural malformations (PMID: 3441503). Coproporphyrinogen III oxidase is deficient in hereditary coproporphyria. These persons usually have enhanced excretion even in a subclinical state of the disease.(PubMed ID 14605502 ) [HMDB]. Coproporphyrinogen III is found in many foods, some of which are cucumber, climbing bean, horseradish, and pepper (c. frutescens). COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Coproporphyrinogen I

3-[9,14,19-tris(2-carboxyethyl)-5,10,15,20-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1(20),3,5,8,10,13,15,18-octaen-4-yl]propanoic acid

C36H44N4O8 (660.3159)


Coproporphyrinogen I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrinogen I is a tetrapyrrole dead-end product resulting from the spontaneous oxidation of the methylene bridges of coproporphyrinogen arising from heme synthesis. It is secreted in feces and urine. Coproporphyrinogen I is biosynthesized from the tetrapyrrole hydroxymethylbilane, which is converted by the action of uroporphyrinogen synthase to uroporphyrinogen I. Uroporphyrinogen I is subsequently converted into coproporphyrinogen I through a series of four decarboxylations. Increased levels of coproporphyrinogens can indicate congenital erythropoietic porphyria or sideroblastic anemia, which are inherited disorders. Porphyria is a pathological state characterized by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: (1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, (2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, and (3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors include disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss and diminished utilization of coproporphyrinogen in the hepatocytes. This may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine. Decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion. Therefore, the coproporphyrin ring isomer ratio becomes a sensitive index for impaired liver function, intrahepatic cholestasis, and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms (PMID: 3327428). Under certain conditions, coproporphyrinogen I can act as a phototoxin, a neurotoxin, and a metabotoxin. A phototoxin leads to cell damage upon exposure to light. A neurotoxin causes damage to nerve cells and nerve tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of porphyrins are associated with porphyrias such as porphyria variegate, acute intermittent porphyria, hereditary coproporphyria (HCP), congenital erythropoietic porphyria, and sideroblastic anemia. There are several types of porphyrias (most are inherited). Hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain, and an acute polyneuropathy), while the erythropoietic forms present with skin problems (usually a light-sensitive blistering rash and increased hair growth). The neurotoxicity of porphyrins may be due to their selective interactions with tubulin, which disrupt microtubule formation and cause neural malformations (PMID: 3441503). Coproporphyrinogen I can be found in a number of food items, including cascade huckleberry, hyacinth bean, horseradish tree, and watercress. Formed by Uroporphyrinogen decarboxylase from Uroporphyrinogen I by decarboxylation of 4 acetates. [HMDB]. Coproporphyrinogen I is found in many foods, some of which are alpine sweetvetch, japanese persimmon, komatsuna, and celery leaves.

   

[(2R,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-sulfooxy-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl] hexadecanoate

[(2R,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-sulfooxy-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl] hexadecanoate

C28H52O15S (660.3027)


   

Capsianoside I

(2E,6E,10E)-14-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

C32H52O14 (660.3357)


Capsianosides are acyclic diterpene glycosides, water-soluble constituents present in the fruits of Paprika (Paprika Capsicum annuum L. var. grossum Bailey) and Jalapeno (Jalapeno Capsicum annuum L. var. annuum), that are used as vegetables and spices. Paprika is known for its high vitamin C content and has been isolated from Hungarian paprika in large amounts. Jalapeno is a stimulating spice which contains capsaicin and related compounds in its fruits and veins. (PMID: 17015971). The genus Capsicum (Solanaceae) includes many species widely cultivated in Asia, Africa, and Mediterranean countries. Peppers are native plants of America, and the fruits (pericarps) are consumed as vegetable foods, spices, and external medicines and are also a source of vitamins A, C, and E. Hot chili pepper has been used for centuries as a condiment to aid digestion. Traditionally, medical doctors advise ulcer patients not to consume spicy foods like pungent capsicum products, while naturopaths and herbalists have tended to use hot seasonings to relieve ulcers. Phytochemical investigations have been mainly focused on hot components of pepper species and qualitative and quantitative determinations of phenolic metabolites with antioxidant activities. (PMID: 17002415). Constituent of Capsicum annuum variety fascuilatum

   

PA(10:0/PGE2)

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(10:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGE2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(PGE2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/10:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/PGD2)

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(10:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGD2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(PGD2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/10:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-(decanoyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O11P (660.3638)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Taccalonolide B

[(1S,2S,3R,5S,7S,9S,10R,11R,12S,13S,14R,15R,16S,17S,22S,23S,24R,25R)-10,14-diacetyloxy-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.02,12.05,11.07,9.016,24.019,23]pentacos-18-en-13-yl] acetate

C34H44O13 (660.2782)


Taccalonolide B is a natural product found in Tacca plantaginea and Tacca chantrieri with data available. Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC50 of 208 nM[1][2]. Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC50 of 208 nM[1][2].

   

Khekadaengoside C

Khekadaengoside C

C36H52O11 (660.3509)


   

Wikstroelide J

Wikstroelide J

C36H52O11 (660.3509)


   

Gambogoic acid A

Gambogoic acid A

C39H48O9 (660.3298)


   

Khekadaengoside I

Khekadaengoside I

C36H52O11 (660.3509)


   

12-O-Deacetyltrichilin H

12-O-Deacetyltrichilin H

C34H44O13 (660.2782)


A limonoid isolated from the ripe fruits of Melia azedarach.

   

(-)-Reveromycin B

(-)-Reveromycin B

C36H52O11 (660.3509)


   

Reveromycin A

Reveromycin A

C36H52O11 (660.3509)


   

14alpha,15beta-diacetoxy-3beta,7beta-dibenzoyloxy-17-hydroxy-9-oxo-2betaH,13betaH-jatropha-5E,11E-diene|17-hydroxy-euphoscopin C

14alpha,15beta-diacetoxy-3beta,7beta-dibenzoyloxy-17-hydroxy-9-oxo-2betaH,13betaH-jatropha-5E,11E-diene|17-hydroxy-euphoscopin C

C38H44O10 (660.2934)


   
   

19-hydroxyervafoline

19-hydroxyervafoline

C40H44N4O5 (660.3312)


   
   

16alpha,17-dihydroxy-ent-kauran-19-oic acid, 16-O-beta-D-glucopyranoside 19-O-beta-D-glucopyranosyl|acantrifoside D|beta-D-glucopyranosyl 17-hydroxy-ent-kauran-19-oate-16-O-beta-D-glucopyranoside

16alpha,17-dihydroxy-ent-kauran-19-oic acid, 16-O-beta-D-glucopyranoside 19-O-beta-D-glucopyranosyl|acantrifoside D|beta-D-glucopyranosyl 17-hydroxy-ent-kauran-19-oate-16-O-beta-D-glucopyranoside

C32H52O14 (660.3357)


   

3,11,22-Trioxo-16??-hydroxy-(20S,24)-epoxy-cucurbit-5,23-diene-2??-O-??-D-glucopyranoside

3,11,22-Trioxo-16??-hydroxy-(20S,24)-epoxy-cucurbit-5,23-diene-2??-O-??-D-glucopyranoside

C36H52O11 (660.3509)


   

1-O-detigloyl-1-O-cinnamoylohchinolal

1-O-detigloyl-1-O-cinnamoylohchinolal

C38H44O10 (660.2934)


   

xylorumphiin A

xylorumphiin A

C35H48O12 (660.3146)


   

3-deacetyltrichilin H

3-deacetyltrichilin H

C34H44O13 (660.2782)


   

pre-segetanin

pre-segetanin

C34H44O13 (660.2782)


   

1alpha,11beta-diacetoxy-4alpha-carbomethoxy-7alpha-hydroxy-12alpha-(2-methylpropanoyloxy)-15-oxohavanensin

1alpha,11beta-diacetoxy-4alpha-carbomethoxy-7alpha-hydroxy-12alpha-(2-methylpropanoyloxy)-15-oxohavanensin

C35H48O12 (660.3146)


   

2-O-beta-D-glucopyranosyl cucurbitacin S

2-O-beta-D-glucopyranosyl cucurbitacin S

C36H52O11 (660.3509)


   

(+/-)-chartaceone F

(+/-)-chartaceone F

C41H40O8 (660.2723)


   
   

21,24,25-triacetyl-7-deacetyl-6-hydroxylbrujavanone E

21,24,25-triacetyl-7-deacetyl-6-hydroxylbrujavanone E

C36H52O11 (660.3509)


   
   

(+/-)-chartaceone C

(+/-)-chartaceone C

C41H40O8 (660.2723)


   

(+/-)-chartaceone D

(+/-)-chartaceone D

C41H40O8 (660.2723)


   

(+/-)-chartaceone E

(+/-)-chartaceone E

C41H40O8 (660.2723)


   

Taccalonolide I

Taccalonolide I

C34H44O13 (660.2782)


   

Taccalonolide F

Taccalonolide F

C34H44O13 (660.2782)


   
   

3beta-O-(4-deoxy-beta-D-hex-4-enopyranosyluronic acid), 2beta-hydroxy-olean-12-en-23,18-dioic acid

3beta-O-(4-deoxy-beta-D-hex-4-enopyranosyluronic acid), 2beta-hydroxy-olean-12-en-23,18-dioic acid

C36H52O11 (660.3509)


   

01-185-17-8|PNG01-185-017-8|PNG01-185-17-8

01-185-17-8|PNG01-185-017-8|PNG01-185-17-8

C39H48O9 (660.3298)


   

Trp Leu Lys Ser Asn

Trp Leu Lys Ser Asn

C31H48N8O8 (660.3595)


   

3,7-O-diacetyl-5,14-O-dibenzoyl-13,17-oxypremyrsinol

3,7-O-diacetyl-5,14-O-dibenzoyl-13,17-oxypremyrsinol

C38H44O10 (660.2934)


   

3_,14_-O-diacetoxy-5_-7_-O-dibenzoyloxy-15_-hydroxy-17,13-oxypremyrsinol

"3_,14_-O-diacetoxy-5_-7_-O-dibenzoyloxy-15_-hydroxy-17,13-oxypremyrsinol "

C38H44O10 (660.2934)


   

C32H52O14_(2E,6E,10E)-14-{[2-O-(beta-D-Glucopyranosyl)-beta-D-glucopyranosyl]oxy}-4-hydroxy-2,6,10,14-tetramethyl-2,6,10,15-hexadecatetraenoic acid

NCGC00384793-01_C32H52O14_(2E,6E,10E)-14-{[2-O-(beta-D-Glucopyranosyl)-beta-D-glucopyranosyl]oxy}-4-hydroxy-2,6,10,14-tetramethyl-2,6,10,15-hexadecatetraenoic acid

C32H52O14 (660.3357)


   

(2E,6E,10E)-14-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

(2E,6E,10E)-14-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

C32H52O14 (660.3357)


   

3,14-O-diacetyl-5-7-O-dibenzoyl-13,17-oxypremyrsinol

3,14-O-diacetyl-5-7-O-dibenzoyl-13,17-oxypremyrsinol

C38H44O10 (660.2934)


   

(2E,6E,10E)-14-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid_major

(2E,6E,10E)-14-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid_major

C32H52O14 (660.3357)


   

His Arg Trp Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

His Arg Tyr Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

His Trp Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

His Trp Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

His Tyr Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

His Tyr Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Asn Arg Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Asn Trp Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Asn Trp Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Arg His Trp Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg His Tyr Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Asn Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Trp His Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Trp Asn Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Trp Trp Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanoic acid

C32H40N10O6 (660.3132)


   

Arg Trp Tyr His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Tyr His Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Arg Tyr Trp His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp His Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp His Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Trp Asn Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp Asn Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Trp Arg His Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp Arg Asn Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp Arg Trp Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanoic acid

C32H40N10O6 (660.3132)


   

Trp Arg Tyr His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Trp Trp Asn Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Trp Trp Arg Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanoic acid

C32H40N10O6 (660.3132)


   

Trp Tyr His Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Trp Tyr Arg His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Tyr His Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Tyr His Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Tyr Arg His Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Tyr Arg Trp His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Tyr Trp His Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H40N10O6 (660.3132)


   

Tyr Trp Arg His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C32H40N10O6 (660.3132)


   

Capsianside I

Capsianoside I

C32H52O14 (660.3357)


   

OKDdiA-PA

1-(9Z-octadecenoyl)-2-(9-oxo-11-carboxy-10E-undecenoyl)-sn-glycero-3-phosphate

C33H57O11P (660.3638)


   

(R)-(+)-2,2-BIS(N-DIPHENYLPHOSPHINOAMINO)-5,5,6,6,7,7,8,8-OCTAHYDRO-1,1-BINAPHTHYL

(R)-(+)-2,2-BIS(N-DIPHENYLPHOSPHINOAMINO)-5,5,6,6,7,7,8,8-OCTAHYDRO-1,1-BINAPHTHYL

C44H42N2P2 (660.2823)


   

5-DMT-2-TBDMS-RU

5-DMT-2-TBDMS-RU

C36H44N2O8Si (660.2867)


5'-O-DMT-2'-TBDMS-Uridine is a deoxyribonucleoside used for the oligonucleotide synthesis.

   

1,3,3-Trimethyl-2-[(E)-2-{(3E)-2-[(1-phenyl-1H-tetrazol-5-yl)sulf anyl]-3-[(2E)-2-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)e thylidene]-1-cyclohexen-1-yl}vinyl]-3H-indolium chloride

1,3,3-Trimethyl-2-[(E)-2-{(3E)-2-[(1-phenyl-1H-tetrazol-5-yl)sulf anyl]-3-[(2E)-2-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)e thylidene]-1-cyclohexen-1-yl}vinyl]-3H-indolium chloride

C39H41ClN6S (660.2802)


   

Metkephamid acetate

Metkephamid acetate

C31H44N6O8S (660.2941)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004745 - Enkephalins

   

12-Ethyl-71,71-dihydroxy-8-isobutylbacteriochlorophyllide c

12-Ethyl-71,71-dihydroxy-8-isobutylbacteriochlorophyllide c

C37H40MgN4O6-2 (660.2798)


   
   
   
   
   

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C33H57O11P (660.3638)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0)

C33H57O11P (660.3638)


   

(+-)-chartaceone C

(+-)-chartaceone C

C41H40O8 (660.2723)


A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and 6-carboxy-1-phenylhex-2-en-1-yl groups at positions 6 and 8 respectively. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.

   

(+-)-chartaceone F

(+-)-chartaceone F

C41H40O8 (660.2723)


A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and 6-carboxy-1-phenylhex-1-en-3-yl groups at positions 6 and 8 respectively. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.

   

(+-)-chartaceone D

(+-)-chartaceone D

C41H40O8 (660.2723)


A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7, 6-carboxy-1-phenylhex-2-en-1-yl group at positions 6 and a 6-carboxy-1-phenylhex-1-en-3-yl group at position 8. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.

   

(+-)-chartaceone E

(+-)-chartaceone E

C41H40O8 (660.2723)


A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7, a 6-carboxy-1-phenylhex-2-en-1-yl group at position 8 and 6-carboxy-1-phenylhex-2-en-3-yl groups at position 6. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.

   

2-{5-[2-tert-butyl-7-(diethylamino)-4H-chromen-4-ylidene]penta-1,3-dien-1-yl}-1-(5-carboxypentyl)-3,3-dimethyl-3H-indolium-5-sulfonate

2-{5-[2-tert-butyl-7-(diethylamino)-4H-chromen-4-ylidene]penta-1,3-dien-1-yl}-1-(5-carboxypentyl)-3,3-dimethyl-3H-indolium-5-sulfonate

C38H48N2O6S (660.3233)


   

N-[(3S,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide

C40H44N4O5 (660.3312)


   

N-[(3R,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[[(3S,9R,10R)-16-(benzenesulfonamido)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-4-(dimethylamino)-N-methylbutanamide

N-[[(3S,9R,10R)-16-(benzenesulfonamido)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-4-(dimethylamino)-N-methylbutanamide

C34H52N4O7S (660.3557)


   

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C37H48N4O7 (660.3523)


   

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)


   

[(2S,4S,5R,6R,7R,10S,12S,13R,14R,15R)-12-acetyloxy-2,10-bis[(2S)-2-acetyloxypropyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadec-4-yl] acetate

[(2S,4S,5R,6R,7R,10S,12S,13R,14R,15R)-12-acetyloxy-2,10-bis[(2S)-2-acetyloxypropyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadec-4-yl] acetate

C32H52O14 (660.3357)


   

Smgdg O-18:5_5:0

Smgdg O-18:5_5:0

C32H52O12S (660.3179)


   

Smgdg O-20:5_3:0

Smgdg O-20:5_3:0

C32H52O12S (660.3179)


   

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C31H49O13P (660.2911)


   

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C31H49O13P (660.2911)


   

coproporphyrinogen III

coproporphyrinogen III

C36H44N4O8 (660.3159)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Coproporphyrinogen I

Coproporphyrinogen I

C36H44N4O8 (660.3159)


   

Capsianoside I

Capsianoside I

C32H52O14 (660.3357)


   
   
   
   
   
   
   
   

PA 18:1/12:3;O3

PA 18:1/12:3;O3

C33H57O11P (660.3638)


   

PA 18:2/12:2;O3

PA 18:2/12:2;O3

C33H57O11P (660.3638)


   
   
   
   
   

PG P-18:0/9:4;O2

PG P-18:0/9:4;O2

C33H57O11P (660.3638)


   

PG P-18:1/8:4;O3

PG P-18:1/8:4;O3

C32H53O12P (660.3274)


   

PG P-20:1/7:3;O2

PG P-20:1/7:3;O2

C33H57O11P (660.3638)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

ST 26:1;O8;GlcA

ST 26:1;O8;GlcA

C32H52O14 (660.3357)


   

ST 28:7;O7;GlcA

ST 28:7;O7;GlcA

C34H44O13 (660.2782)


   

ST 29:6;O6;GlcA

ST 29:6;O6;GlcA

C35H48O12 (660.3146)


   

ST 29:7;O7;Hex

ST 29:7;O7;Hex

C35H48O12 (660.3146)


   

Boc-Glu-Lys-Lys-AMC

Boc-Glu-Lys-Lys-AMC

C32H48N6O9 (660.3483)


Boc-Glu-Lys-Lys-AMC is a sensitive fluorogenic substrate for urokinase-activated plasmin[1].

   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 14-(hydroxymethyl)-5,9-dimethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 14-(hydroxymethyl)-5,9-dimethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C32H52O14 (660.3357)


   

4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-14-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate

6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-14-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate

C35H48O12 (660.3146)


   

(2r)-1-[(2s,4s,5r,6s,7s,10s,12s,13r,14s,15s)-4,12-bis(acetyloxy)-10-[(2r)-2-(acetyloxy)propyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadecan-2-yl]propan-2-yl acetate

(2r)-1-[(2s,4s,5r,6s,7s,10s,12s,13r,14s,15s)-4,12-bis(acetyloxy)-10-[(2r)-2-(acetyloxy)propyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadecan-2-yl]propan-2-yl acetate

C32H52O14 (660.3357)


   

(1s,2r,4r,5r,6s,8r,10r,11s,12r,14r,15r,16s,19r,20r,21s)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

(1s,2r,4r,5r,6s,8r,10r,11s,12r,14r,15r,16s,19r,20r,21s)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-3-phenylprop-2-enoate

(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-3-phenylprop-2-enoate

C38H44O10 (660.2934)


   

(1s,2s,4r,5s,7s,9s,10r,11s,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

(1s,2s,4r,5s,7s,9s,10r,11s,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)


   

methyl 5,9-dimethyl-14-methylidene-15-{[3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

methyl 5,9-dimethyl-14-methylidene-15-{[3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H52O11 (660.3509)


   

2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl 3-phenylprop-2-enoate

2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl 3-phenylprop-2-enoate

C38H44O10 (660.2934)


   

(2e,4r,6e,10e,14s)-14-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

(2e,4r,6e,10e,14s)-14-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

C32H52O14 (660.3357)


   

(2e,6e,10e)-14-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

(2e,6e,10e)-14-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

C32H52O14 (660.3357)


   

3,11,22-trioxo-16α-hydroxy-(20s,24)-epoxy-cucurbit-5,23-diene-2β-o-β-d-glucopyrano-side

NA

C36H52O11 (660.3509)


{"Ingredient_id": "HBIN006895","Ingredient_name": "3,11,22-trioxo-16\u03b1-hydroxy-(20s,24)-epoxy-cucurbit-5,23-diene-2\u03b2-o-\u03b2-d-glucopyrano-side","Alias": "NA","Ingredient_formula": "C36H52O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21969","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3-deacetyltrichilin h

NA

C34H44O13 (660.2782)


{"Ingredient_id": "HBIN008414","Ingredient_name": "3-deacetyltrichilin h","Alias": "NA","Ingredient_formula": "C34H44O13","Ingredient_Smile": "NA","Ingredient_weight": "660.714","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8154","PubChem_id": "NA","DrugBank_id": "NA"}

   

acantrifoside d

NA

C32H52O14 (660.3357)


{"Ingredient_id": "HBIN014359","Ingredient_name": "acantrifoside d","Alias": "NA","Ingredient_formula": "C32H52O14","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "93","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,4s,5r,9s,10r,13s,14r)-14-hydroxy-5,9,14-trimethyl-13-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,4s,5r,9s,10r,13s,14r)-14-hydroxy-5,9,14-trimethyl-13-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C32H52O14 (660.3357)


   

10-[9-butyl-8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

10-[9-butyl-8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)


   

(2z)-4-[(1s,2s,8r,15s,16s,17s,19r)-12-hydroxy-16-methoxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1s,2s,8r,15s,16s,17s,19r)-12-hydroxy-16-methoxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

C39H48O9 (660.3298)


   

(2r,3s,3as,6r,12r,13r,13ar)-13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate

(2r,3s,3as,6r,12r,13r,13ar)-13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate

C38H44O10 (660.2934)


   

methyl (1s,2r,4s,6s,7r,8r,9r,10r,11s,12s,14r,15s,16r,18r)-8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate

methyl (1s,2r,4s,6s,7r,8r,9r,10r,11s,12s,14r,15s,16r,18r)-8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate

C35H48O12 (660.3146)


   

chartaceone c

chartaceone c

C41H40O8 (660.2723)


   

20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

(1r,2s,4s,5s,6r,8s,10r,11r,12s,14s,15s,16r,19s,20s,21r)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

(1r,2s,4s,5s,6r,8s,10r,11r,12s,14s,15s,16r,19s,20s,21r)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

(2e)-3-[(1s,3s,6r)-3-({[(2e)-3-[(1s,2s,3s,6r)-3-(chloromethyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoyl]oxy}methyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

(2e)-3-[(1s,3s,6r)-3-({[(2e)-3-[(1s,2s,3s,6r)-3-(chloromethyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoyl]oxy}methyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

C32H49ClO12 (660.2912)


   

(1r,2r,3as,3br,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3br,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)


   

2-hydroxy-1-(2-hydroxy-6-methyl-3-oxohept-6-en-2-yl)-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

2-hydroxy-1-(2-hydroxy-6-methyl-3-oxohept-6-en-2-yl)-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)


   

(1s,2r,3r,5s,7s,9s,10r,11r,12s,13r,14r,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-3,13,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

(1s,2r,3r,5s,7s,9s,10r,11r,12s,13r,14r,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-3,13,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4s,5r,9s,10r,13r,14r)-14-(hydroxymethyl)-5,9-dimethyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4s,5r,9s,10r,13r,14r)-14-(hydroxymethyl)-5,9-dimethyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C32H52O14 (660.3357)


   

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)


   

13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate

13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate

C38H44O10 (660.2934)


   

13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)


   

10-[(acetyloxy)methyl]-2,4,10,11,12-pentahydroxy-2,6,14,14-tetramethyl-9-[(2-methylbut-2-enoyl)oxy]-3,13-dioxotricyclo[10.3.0.0⁴,⁸]pentadecan-7-yl benzoate

10-[(acetyloxy)methyl]-2,4,10,11,12-pentahydroxy-2,6,14,14-tetramethyl-9-[(2-methylbut-2-enoyl)oxy]-3,13-dioxotricyclo[10.3.0.0⁴,⁸]pentadecan-7-yl benzoate

C34H44O13 (660.2782)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 14-hydroxy-5,9,14-trimethyl-13-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 14-hydroxy-5,9,14-trimethyl-13-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C32H52O14 (660.3357)


   

1-[4,12-bis(acetyloxy)-10-[2-(acetyloxy)propyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadecan-2-yl]propan-2-yl acetate

1-[4,12-bis(acetyloxy)-10-[2-(acetyloxy)propyl]-6,14-dihydroxy-5,7,13,15-tetramethyl-8,16-dioxo-1,9-dioxacyclohexadecan-2-yl]propan-2-yl acetate

C32H52O14 (660.3357)


   

(1s,2r,4r,5s,6r,8s,10r,11s,12s,14r,15r,16s,19r,20s,21r)-4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

(1s,2r,4r,5s,6r,8s,10r,11s,12s,14r,15r,16s,19r,20s,21r)-4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

(1s,2r,3r,7s,9r,11s,12s,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-5,10,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-3-yl acetate

(1s,2r,3r,7s,9r,11s,12s,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-5,10,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-3-yl acetate

C34H44O13 (660.2782)


   

(1s,2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

(1s,2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

C36H52O11 (660.3509)


   

reveromycin b

reveromycin b

C36H52O11 (660.3509)


   

methyl 9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate

methyl 9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate

C35H48O12 (660.3146)


   

methyl (1r,4s,5r,9s,10r,13r,15r)-5,9-dimethyl-14-methylidene-15-{[(2r,3r,4r,5r,6r)-3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

methyl (1r,4s,5r,9s,10r,13r,15r)-5,9-dimethyl-14-methylidene-15-{[(2r,3r,4r,5r,6r)-3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H52O11 (660.3509)


   

(1s,2s,3r,5s,7s,9s,10r,11r,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

(1s,2s,3r,5s,7s,9s,10r,11r,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)


   

methyl 8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate

methyl 8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate

C35H48O12 (660.3146)


   

(2e,4r,5r,6e,8e)-10-[(2s,3r,6r,8r,9s)-9-butyl-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4r,5r,6e,8e)-10-[(2s,3r,6r,8r,9s)-9-butyl-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)


   

methyl (1s,3ar,3br,4r,5ar,6s,7r,9s,9as,9bs,10r,11r,11as)-9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate

methyl (1s,3ar,3br,4r,5ar,6s,7r,9s,9as,9bs,10r,11r,11as)-9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate

C35H48O12 (660.3146)


   

(1s,2s,4r,6s,7s,8r,9s,10r,13s,14s)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6s,7s,8r,9s,10r,13s,14s)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)


   

14-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

14-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoic acid

C32H52O14 (660.3357)


   

(1s,2r,4r,5r,6s,8r,11s,12r,14r,15r,16s,19r,20r,21s)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

(1s,2r,4r,5r,6s,8r,11s,12r,14r,15r,16s,19r,20r,21s)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate

C34H44O13 (660.2782)


   

(1s,2r,3r,4s,5r,7s,8r,9s,10r,13r,15r)-2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-3-phenylprop-2-enoate

(1s,2r,3r,4s,5r,7s,8r,9s,10r,13r,15r)-2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-3-phenylprop-2-enoate

C38H44O10 (660.2934)


   

4-[12-hydroxy-16-methoxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

4-[12-hydroxy-16-methoxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid

C39H48O9 (660.3298)


   

(1r,2s,4r,6s,7s,8r,9r,10r,11s,12r)-10-[(acetyloxy)methyl]-2,4,10,11,12-pentahydroxy-2,6,14,14-tetramethyl-9-{[(2z)-2-methylbut-2-enoyl]oxy}-3,13-dioxotricyclo[10.3.0.0⁴,⁸]pentadecan-7-yl benzoate

(1r,2s,4r,6s,7s,8r,9r,10r,11s,12r)-10-[(acetyloxy)methyl]-2,4,10,11,12-pentahydroxy-2,6,14,14-tetramethyl-9-{[(2z)-2-methylbut-2-enoyl]oxy}-3,13-dioxotricyclo[10.3.0.0⁴,⁸]pentadecan-7-yl benzoate

C34H44O13 (660.2782)


   

n-(1-acetyl-2-oxopyrrolidin-3-yl)-3-hydroxy-4-{[hydroxy(2-{3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl}-1,2-diazinan-3-yl)methylidene]amino}-2-methyl-5-phenylpentanimidic acid

n-(1-acetyl-2-oxopyrrolidin-3-yl)-3-hydroxy-4-{[hydroxy(2-{3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl}-1,2-diazinan-3-yl)methylidene]amino}-2-methyl-5-phenylpentanimidic acid

C32H48N6O9 (660.3483)


   

13,14-bis(acetyloxy)-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

13,14-bis(acetyloxy)-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)


   

(1s,2r,6r,7r,10r,11s,12s,14s,15s,16r,18r)-6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-14-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate

(1s,2r,6r,7r,10r,11s,12s,14s,15s,16r,18r)-6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-14-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate

C35H48O12 (660.3146)


   

(2s,3s,4s)-n-[(3s)-1-acetyl-2-oxopyrrolidin-3-yl]-3-hydroxy-4-({hydroxy[(3s)-2-[(2r,3r)-3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl]-1,2-diazinan-3-yl]methylidene}amino)-2-methyl-5-phenylpentanimidic acid

(2s,3s,4s)-n-[(3s)-1-acetyl-2-oxopyrrolidin-3-yl]-3-hydroxy-4-({hydroxy[(3s)-2-[(2r,3r)-3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl]-1,2-diazinan-3-yl]methylidene}amino)-2-methyl-5-phenylpentanimidic acid

C32H48N6O9 (660.3483)


   

(2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

(2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

C36H52O11 (660.3509)


   

(2e,4s,5s,6e,8e)-10-[(2r,7r,8s)-2-butyl-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4s,5s,6e,8e)-10-[(2r,7r,8s)-2-butyl-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)


   

(1s,2s,4r,6s,7r,8r,9r,10r,13r,14r)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6s,7r,8r,9r,10r,13r,14r)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)


   

7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)


   

(1s,2s,4r,5s,7s,9s,10r,11s,12s,13s,14r,15r,16s,17s,22r,23s,25r)-13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

(1s,2s,4r,5s,7s,9s,10r,11s,12s,13s,14r,15r,16s,17s,22r,23s,25r)-13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate

C34H44O13 (660.2782)